|
We at ViroPharma are in turn dedicated to physician education, and bringing new products to them.
Initially, on ViroPharma’s acquisition of VANCOCIN in 2004, rather than developing a sales organization to promote the drug we made the business decision to focus our attention on physician education and ensuring patient safety. Our objectives today are clear, and include assisting physicians in their work to assure the safety of, and appropriate therapies for, patients with severe C. difficile infections or hereditary angioedema (HAE).
Our focus will remain on physician education, but our broader ambitions also include developing new important drugs for other diseases, including those caused by C1 esterase inhibitor deficiency and recurrent CDI to improve the lives of patients.
Learn more about two of our therapeutic areas, gastroenterology and hospital/transplant medicine.
|
|
ViroPharma Named Patient Program
Facilitating physicians access in countries other than the United States to certain ViroPharma investigational or pre-approval products, which may be administered to individual patients suffering from serious illnesses and who have no other therapeutic options. Learn More 
Investigator Initiated Studies (IIS)
Providing research grants of clinical supplies and/or funding to support scientifically compelling research consistent with our therapeutic interests and to address legitimate medical or scientific questions. Learn More 
Educational Grants
Providing funding in the form of an unrestricted, educational grant to support support health care provider education, advance the quality of patient care and align with ViroPharma’s therapeutic or clinical interests. Learn More
|